Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

31:09
 
Share
 

Manage episode 513061827 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

  • Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
  • Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
  • Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications

  continue reading

767 episodes

Artwork
iconShare
 
Manage episode 513061827 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

  • Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
  • Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
  • Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications

  continue reading

767 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play